Research Article

Serum Procalcitonin and Presepsin Levels in Patients with Generalized Pustular Psoriasis

Makoto Nagai, Yasutomo Imai, Yoshihiro Wada, Minori Kusakabe, and Kiyofumi Yamanishi

Department of Dermatology, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan

Correspondence should be addressed to Yasutomo Imai; imai-yas@hyo-med.ac.jp and Kiyofumi Yamanishi; kyamanis@hyo-med.ac.jp

Received 24 August 2018; Revised 24 October 2018; Accepted 31 October 2018; Published 16 December 2018

Academic Editor: Alexandra Scholze

Copyright © 2018 Makoto Nagai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Patients with generalized pustular psoriasis (GPP) often present with symptoms that must be differentiated from sepsis. Procalcitonin (PCT) and presepsin (P-SEP) are widely used as biomarkers for sepsis; therefore, we examined the serum PCT and P-SEP levels in patients with psoriatic diseases. The enrolled patients included 27 with psoriasis vulgaris (PV) (22 males, 5 females; mean age 47.7 years), 12 with psoriatic arthritis (PsA) (8 males, 4 females; mean age 51.3 years), and 15 with GPP (10 males, 5 females; mean age 63.7 years). The mean serum PCT levels in patients with PV, PsA, and GPP were 0.01 ng/mL (25th–75th percentile; 0.00–0.03), 0.013 ng/mL (0.00–0.03), and 0.12 ng/mL (0.05–0.18), respectively; the levels of PCT were higher for patients with GPP than with PV or PsA but were lower than the PCT cutoff value (0.5 ng/mL) for the diagnosis of infection. The mean serum P-SEP levels in patients with PV, PsA, and GPP were 144.9 pg/mL (25th–75th percentile; 78–181), 168.1 pg/mL (124–203), and 479.9 pg/mL (216–581), respectively. Unexpectedly, the levels of P-SEP in the patients with GPP were as high as the P-SEP cutoff value (317 to 647 pg/mL) used for the diagnosis of infection. We also found that neutrophils produced P-SEP, suggesting that the high serum P-SEP levels in patients with GPP might arise at least in part due to the P-SEP derived from neutrophils activated in GPP. Both serum PCT and P-SEP might therefore be useful as novel serum biomarkers for GPP because their levels were decreased by GPP treatments. However, the measurement of PCT might be more useful than the measurement of P-SEP for discriminating between GPP and sepsis.

1. Introduction

Procalcitonin (PCT) is a 116-amino-acid precursor peptide of the hormone calcitonin (CT) [1]. In noninfected conditions, PCT is mainly produced as a precursor of CT by the C cells of the thyroid gland. However, PCT can also be produced from nonneuroendocrine tissues due to infections, including sepsis, which contribute to increase in blood PCT levels [2]. Numerous studies on PCT have been published since the ’90s, and PCT is now widely used as a biomarker for bacterial infection or sepsis [3].

Presepsin (P-SEP), a soluble CD14 subtype, is also now recognized as a new sepsis biomarker. P-SEP is a small 13 kDa protein that arises due to cleavage of the N-terminal fragment of CD14 by elastase [4]. Membrane-bound CD14 has a high affinity for bacterial lipopolysaccharide and is expressed on the cell surface of monocytes, macrophages, and neutrophils. Arai et al. reported that monocytes were the main source of P-SEP in humans and that P-SEP secretion by monocytes is triggered by phagocytosis rather than by soluble inflammatory stimuli [5]. Compared with other sepsis markers, including C-reactive protein (CRP) and PCT, P-SEP appears to have a better specificity and sensitivity for the diagnosis of sepsis [4], as blood levels of P-SEP in patients with injuries or burns are almost normal [6].

Psoriasis is a chronic inflammatory skin disease that has several forms [7]. The major form of this disease is psoriasis vulgaris (PV), which is characterized by erythematous plaques with thick scales. Another commonly encountered form is psoriatic arthritis (PsA), a seronegative arthropathy that is
associated with psoriatic skin lesions and characterized by chronic arthritis, dactylitis, and enthesitis. By contrast, GPP is a rarer but more severe subtype of psoriasis and is characterized by multiple sterile pustules that develop all over the body surface [7–9]. Unlike PV or PsA, GPP is associated with a generalized erythematous flush and sepsis-like systemic symptoms, including high fever, leukocytosis, and elevated CRP levels. The severe and intractable inflammatory conditions associated with GPP, which include leukocyte activation, mean that therapy for GPP is typically leukocytapheresis or granulocyte and monocyte apheresis, in addition to administration of methotrexate, cyclosporine, prednisolone, or biologics such as the anti-TNF-alpha antibody infliximab or the anti-IL-17 antibody secukinumab [7, 9].

Psoriasis is possibly triggered by activation of cytokines, such as TNF-alpha, IL-17, IL-12, and IL-23; therefore, these cytokines are now therapeutic targets for the disease [8]. However, considering the sepsis-like manifestations in GPP, we speculated that clinical tests for PCT and P-SEP, the markers of sepsis, might also be candidate biomarkers for GPP. In this study, we examined the serum levels of PCT and P-SEP in psoriatic diseases, and we propose that PCT, but possibly not P-SEP, may be a useful biomarker for GPP.

2. Patients and Methods

2.1. Study Subjects. The enrolled patients included 27 with PV, 12 with PsA, and 15 with GPP (Table 1) treated at the Hyogo College of Hospital, Hyogo, Japan, from January 2006 to December 2017. This study was approved by the Ethics Review Board of Hyogo College of Medicine (no. 212), and informed consent was obtained from all patients. Blood was collected at the baseline or at the first visit (before therapy) and again at follow-ups after treatment, but blood sampling was not necessarily scheduled because additional samplings of human materials, except for clinical need, were not permitted by the Ethics Review Board.

2.2. Measurement of PCT and P-SEP. PCT concentrations were measured using a Brahms procalcitonin (PCT) kit (Wako, Osaka, Japan), and P-SEP concentrations were measured with a chemiluminescence enzyme immunoassay (CLEIA) presespin kit (LSI Medience, Tokyo, Japan) [10]; all procedures were conducted according to the manufacturers’ instructions. The blood samples were analyzed by SRL Kobe Laboratory (SRL Inc., Japan).

2.3. Isolation and Stimulation of Monocytes and Neutrophils. Monocytes were isolated from human whole blood from healthy volunteers using StraightFrom™ Whole Blood CD14 MicroBeads and a Monocyte Isolation Whole Blood Column Kit (Miltenyi Biotec, Bergisch Gladbach, Germany), while neutrophils were isolated using a MACsExpress Neutrophil Isolation Kit (Miltenyi Biotec); all procedures were conducted according to the manufacturers’ instructions. Residual erythrocytes were lysed using ACK Lysing Buffer (Thermo Fisher Scientific, Waltham, MA). The purity of the enriched CD14(+) monocytes (>90%) was evaluated using an anti-CD14 antibody (BD Biosciences, San Jose, CA), and the purity of the CD16(+) neutrophils (>97%) was analyzed using an anti-CD16 antibody (BD Biosciences); all cells were characterized by flow cytometry using an LSR-II instrument (BD Biosciences). Monocytess (2×10⁶ cells per mL) or neutrophils (5×10⁶ cells per mL) were cultured for 5 hours in RPMI 1640 medium containing 10% fetal bovine serum in a 48-well plate (IWAKI, Tokyo, Japan), with or without addition of 0.5 mg/mL of pHrodo Green E. coli BioParticles (Thermo Fisher Scientific). The concentration of P-SEP in the culture medium was then measured.

2.4. Statistics. Data were analyzed using GraphPad Prism version 6 (GraphPad Software Inc., San Diego, CA). Tukey’s multiple comparison test was used for multiple comparisons. A two-tailed unpaired t-test was used for single comparisons. The Wilcoxon matched-pairs signed-rank test was used for intragroup comparison. Correlations were calculated using Spearman’s test. A p value less than 0.05 was considered statistically significant.

3. Results

The enrolled patients included 27 with PV (22 males, 5 females; mean age 47.7 years, range 18–85), 12 with PsA (8 males, 4 females; mean age 51.3 years, range 35–74), and 15 with GPP (10 males, 5 females; mean age 63.7 years, range 36–92) (Table 1).

3.1. Serum PCT Levels in Patients with GPP. Serum PCT levels (at the first visit) were increased in patients with GPP than in patients with PV (Figure 1); the mean serum PCT levels in patients with PV, PsA, and GPP were 0.01 ng/mL (25th–75th percentile; 0.00–0.03), 0.013 ng/mL (0.00–0.03), and 0.12 ng/mL (0.05–0.18), respectively. The serum PCT of healthy individuals is typically below the limit of detection.
in clinical assays (0.01 ng/mL), so levels less than 0.15 ng/mL make the diagnosis of significant bacterial infection "unlikely" [11], whereas levels greater than the cutoff level 0.5 ng/mL are considered appropriate for the diagnosis of infection [12, 13]. Serum PCT levels in patients with GPP were lower than the cutoff level.

3.2. Serum P-SEP Levels in Patient with GPP. Serum P-SEP levels (at the first visit) were significantly increased in patients with GPP (Figure 2) when compared to patients with either PV or PsA; the mean serum P-SEP levels in patients with PV, PsA, and GPP were 144.9 pg/mL (25th–75th percentile; 78–181), 168.1 pg/mL (124–203), and 479.9 pg/mL (216–581), respectively. The normal range of P-SEP in healthy adults is reported as 155 pg/mL (25th–75th percentile; 109–231), and the optimal cutoff values for diagnosing sepsis by CLEIA range from 317 to 647 pg/mL [10]. We found that serum P-SEP levels in patients with GPP were as high as those reported in patients with sepsis.

3.3. Correlations of Serum CRP, PCT, and P-SEP in Patients with GPP. Because serum CRP levels were elevated in patients with GPP, we measured the serum levels of CRP to determine any possible correlations with serum PCT or P-SEP levels. A significant correlation was found between serum PCT and P-SEP levels \( r = 0.522, p < 0.05 \) (Figure 3(a)), whereas no significant correlation was noted between serum CRP levels and either serum PCT or P-SEP levels (Figures 3(b) and 3(c)).

3.4. Serum PCT and P-SEP Levels after Treatment of GPP. The characteristics of patients with GPP and the details of their treatment are shown in Table 2. The high serum PCT and P-SEP levels in 15 patients with GPP before the treatment (the acute exacerbation period) were significantly decreased after treatment (Figure 4).

3.5. Neutrophils Produce P-SEP. Monocytes have recently been identified as the main source of P-SEP, and P-SEP secretion is triggered by phagocytosis rather than soluble inflammatory stimuli [5]. However, neutrophils also play a central role in the pathophysiology of GPP [14], so we hypothesized that neutrophils, as well as monocytes, could produce P-SEP. Indeed, P-SEP production occurred in monocytes as well as in neutrophils isolated from human whole blood from healthy volunteers following stimulation with pHrodo *E. coli* particles (Figure 5).

4. Discussion

The diagnosis of GPP is sometimes difficult, and infection or sepsis should be considered in the differential diagnosis of patients with GPP and high fever [8, 14].

The PCT algorithm in patients with sepsis either encourages (>0.5 ng/mL) [13] or discourages (<0.25 ng/mL) the initiation of antibiotic therapy by monitoring PCT kinetics [12]. In the present study, the serum PCT levels were slightly increased in the patients with GPP (Figure 1), but the mean serum PCT levels in these patients (0.12 ng/mL) were not particularly high; therefore, microbial infection was considered "unlikely."

Measurement of serum P-SEP levels is valuable for the very early diagnosis of sepsis arising from bacterial or fungal infections [15] because rises in P-SEP levels occur 12 to 48
hours earlier than rises are observed in the levels of other biomarkers (e.g., PCT and CRP). Surprisingly, the mean serum P-SEP levels were very high (479.9 pg/mL) in patients with GPP (Figure 2), and this high level might be misinterpreted as a "likely microbial infection, given that the optimal cutoff value for P-SEP in the diagnosis of sepsis is about 500 pg/mL [10]. Therefore, P-SEP might not be of particular value for the differential diagnosis of GPP and sepsis in patients with fever.

Serum PCT levels show a positive correlation with CRP levels in patients with bacterial infection [4, 13]. Conversely, no significant correlations were evident between CRP and PCT or P-SEP levels (Figure 3), which may reflect the fact that GPP is not an infectious disease.

The elevated serum PCT and P-SEP levels in patients with GPP were significantly lowered after GPP treatment (Figure 4). Therefore, PCT and P-SEP could both be useful as novel serum biomarkers for GPP.

PCT has been documented as a marker of bacterial infection. However, PCT also mediates the inflammatory response; for example, high serum PCT levels have been reported in patients with Kawasaki disease [16] or with invasive trauma [4]. By contrast, the values of P-SEP do not show a similar elevation, even in patients with trauma [4]. In this respect, P-SEP, unlike PCT, appears to be highly disease specific.

The finding of very high serum P-SEP levels in patients with GPP was surprising (Figure 2).

P-SEP is a truncated fragment of the CD14 N-terminal, and both monocytes and neutrophils express CD14 on their membranes [17]. The production of P-SEP by monocytes, but not by neutrophils, has recently been reported in response to E. coli particles [5]. The incubation time of the cells with E. coli particles in the previous report was 3 hours, but we detected P-SEP production by neutrophils after 5 hours of incubation (Figure 5). Because neutrophils have a

---

**Figure 3**: Correlations of serum procalcitonin (PCT), presepsin (P-SEP), and C-reactive protein (CRP). Correlations between serum PCT and P-SEP (a), between PCT and CRP (b), and between PCT and CRP (c).

**Table 2**: Characteristics of the study patients with generalized pustular psoriasis (GPP), showing the serum inflammatory marker levels before and after treatment in 15 patients.

| Age (years) | Sex | Baseline PCT (ng/mL) | Follow-up PCT | Baseline P-SEP (pg/mL) | Follow-up P-SEP | Baseline CRP (mg/dL) | Follow-up CRP | Treatment |
|-------------|-----|----------------------|---------------|------------------------|----------------|---------------------|---------------|-----------|
| 76          | M   | 0.07                 | <0.02         | 581                    | 269            | 6.2                 | 0.7           | Etretinate |
| 73          | M   | 5.58                 | 0.07          | 7190                   | 807            | 23.7                | 4.5           | LCAP      |
| 55          | M   | 1.09                 | <0.02         | 1220                   | 291            | 7.7                 | 0.1           | MTX+CyA   |
| 70          | M   | 0.03                 | <0.02         | 538                    | 267            | 4.7                 | 0.1           | Etretinate+PSL |
| 62          | F   | 0.45                 | 0.03          | 609                    | 120            | 26.2                | 0.3           | MTX       |
| 71          | M   | 0.06                 | 0.03          | 526                    | 209            | 4.4                 | 1.2           | PSL       |
| 67          | M   | 0.07                 | 0.04          | 757                    | 210            | 14.5                | 0.2           | IFX       |
| 54          | F   | 0.35                 | <0.02         | 301                    | 125            | 22.2                | 0.2           | IFX       |
| 55          | M   | 0.18                 | 0.06          | 1200                   | 834            | 5.8                 | 1.7           | MTX+CyA   |
| 57          | M   | <0.02                | <0.02         | 195                    | 116            | 1                   | 0.1           | GMA       |
| 62          | M   | 0.25                 | 0.08          | 1160                   | 631            | 10.3                | 0.2           | CyA       |
| 92          | M   | 0.28                 | 0.04          | 173                    | 223            | 0.1                 | 0.2           | GMA       |
| 78          | F   | 0.07                 | 0.03          | 450                    | 308            | 1.5                 | 0.5           | GMA       |
| 52          | F   | 0.04                 | 0.03          | 146                    | 162            | 3.9                 | 0.1           | PSL       |
| 36          | F   | 0.08                 | 0.03          | 434                    | 192            | 8.15                | 0.15          | SEC       |

PCT: procalcitonin; P-SEP: presepsin; CRP: C-reactive protein; LCAP: leukocytapheresis; MTX: methotrexate; CyA: cyclosporine; PSL: prednisolone; IFX: infliximab; GMA: granulocyte and monocyte apheresis; SEC: secukinumab.
known involvement in the disease process of GPP [14], our data suggest that the high serum P-SEP levels observed in patients with GPP might arise at least partly from P-SEP derived from neutrophils.

GPP is an autoinflammatory skin disorder, and infection is only one of the triggering factors for GPP. Even after the triggering factors have diminished, patients with GPP continue to show generalized inflammatory conditions, such as multiple sterile pustules with neutrophil infiltrates in the skin, fever, and increases in CRP [5]. The observed high serum P-SEP levels in GPP might reflect a sterile activation of P-SEP-producing cells, such as monocytes and/or neutrophils. However, further study is required to elucidate mechanisms responsible for the increase in serum P-SEP levels.

This study has some limitations. In particular, GPP is a very rare disease, so enrolment of large numbers of patients was difficult.

Taken together, our findings suggest that P-SEP might not be useful for distinguishing between GPP and sepsis, because the P-SEP levels in patients with GPP were as high as the cutoff level for sepsis. In conclusion, we propose that the measurement of PCT levels could be useful for discriminating between GPP and sepsis.

Data Availability
No data were used to support this study.

Conflicts of Interest
The authors have no financial conflicts of interest.

Authors’ Contributions
Y. I. and K. Y. designed the research; M. N., Y. W., and M. K. collected the data; M. N. and Y. I. performed the in vitro research; M. N., Y. I., and K. Y. analyzed the data; and M. N., Y. I., and K. Y. wrote the paper. Makoto Nagai and Yasutomo Imai equally contributed to this work.

Acknowledgments
We thank Ms. Orie Jitsukawa, Ms. Rumi Uekado, Ms. Saori Kamiyama, and members of the Joint-Use Research Facilities, Hyogo College of Medicine, for their technical assistance. This work was supported in part by JSPS KAKENHI (17K16356 and JP18K08284).

References
[1] M. Assicot, C. Bohuon, D. Gendrel, J. Raymond, H. Carsin, and J. Guilbaud, “High serum procalcitonin concentrations in patients with sepsis and infection,” *Lancet*, vol. 341, no. 8844, pp. 515–518, 1993.
[2] M. Christ-Crain and B. Muller, “Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators,” *European Respiratory Journal*, vol. 30, no. 3, pp. 556–573, 2007.
[3] C. Wacker, A. Prkno, F. M. Brunkhorst, and P. Schlattmann, “Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis,” *The Lancet Infectious Diseases*, vol. 13, no. 5, pp. 426–435, 2013.
4. T. Shozushima, G. Takahashi, N. Matsumoto, M. Kojika, S. Endo, and Y. Okamura, "Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome," *Journal of Infection and Chemotherapy*, vol. 17, no. 6, pp. 764–769, 2011.

5. Y. Arai, K. Mizugishi, K. Nonomura, K. Naitoh, A. Takaori-Kondo, and K. Yamashita, "Phagocytosis by human monocytes is required for the secretion of presepsin," *Journal of Infection and Chemotherapy*, vol. 21, no. 8, pp. 564–569, 2015.

6. K. Shirakawa, K. Naitou, J. Hirose, T. Takahashi, and S. Furusako, "Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients," *Clinical Chemistry and Laboratory Medicine*, vol. 49, no. 5, pp. 937–939, 2011.

7. K. M. Hoegler, A. M. John, M. Z. Handler, and R. A. Schwartz, "Generalized pustular psoriasis: a review and update on treatment," *J Eur Acad Dermatol Venereol*, vol. 32, no. 10, pp. 1645–1651, 2018.

8. M. Yamamoto, Y. Imai, Y. Sakaguchi, T. Haneda, and K. Yamanishi, "Serum cytokines correlated with the disease severity of generalized pustular psoriasis," *Disease Markers*, vol. 34, no. 3, 161 pages, 2013.

9. H. Fujita, T. Terui, K. Hayama et al., "Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP," *The Journal of Dermatology*, vol. 45, no. 11, pp. 1235–1270, 2018.

10. M. Sato, G. Takahashi, S. Shibata et al., "Clinical performance of a new soluble CD14-subtype immunochromatographic test for whole blood compared with chemiluminescent enzyme immunoassay: use of quantitative soluble CD14-subtype immunochromatographic tests for the diagnosis of sepsis," *PLoS One*, vol. 10, no. 12, article e0143971, 2015.

11. P. Dandona, D. Nix, M. F. Wilson et al., "Procalcitonin increase after endotoxin injection in normal subjects," *The Journal of Clinical Endocrinology and Metabolism*, vol. 79, no. 6, pp. 1605–1608, 1994.

12. R. Sager, A. Kutz, B. Mueller, and P. Schuetz, "Procalcitonin-guided diagnosis and antibiotic stewardship revisited," *BMC Medicine*, vol. 15, no. 1, p. 15, 2017.

13. W. S. Lee, D. W. Kang, J. H. Back, H. L. Kim, J. H. Chung, and B. C. Shin, "Cutoff value of serum procalcitonin as a diagnostic biomarker of infection in end-stage renal disease patients," *The Korean Journal of Internal Medicine*, vol. 30, no. 2, pp. 198–204, 2015.

14. S. Ikeda, H. Takahashi, Y. Suga et al., "Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis," *Journal of the American Academy of Dermatology*, vol. 68, no. 4, pp. 609–617, 2013.

15. J. Wu, L. Hu, G. Zhang, F. Wu, and T. He, "Accuracy of presepsin in sepsis diagnosis: a systematic review and meta-analysis," *PLoS One*, vol. 10, no. 7, article e0133057, 2015.

16. S. R. Dominguez, B. Martin, H. Heizer et al., "Procalcitonin (PCT) and Kawasaki disease: does PCT correlate with IVIG-resistant disease, admission to the intensive care unit, or development of coronary artery lesions?,” *Journal of the Pediatric Infectious Diseases Society*, vol. 5, no. 3, pp. 297–302, 2016.

17. P. Antal-Szalmas, I. A. G. van Strijp, A. J. L. Weersink, J. Verhoef, and K. P. M. van Kessel, "Quantitation of surface CD14 on human monocytes and neutrophils," *Journal of Leukocyte Biology*, vol. 61, no. 6, pp. 721–728, 1997.
